August 5, 2009 — The US Food and Drug Administration (FDA) has approved a long-acting, once-monthly formulation of paliperidone palmitate injection (Invega Sustenna, Janssen, a division of ...

Trial is the first to study schizophrenia treatment within the context of many real-world issues faced by patients with schizophrenia TITUSVILLE, N.J., April 15, 2015 /PRNewswire/ -- A study published ...

If you have schizophrenia, your doctor might suggest Invega Trinza as a treatment option for you. Invega Trinza is a prescription medication that treats schizophrenia in adults. It can be used in ...

Invega Sustenna (paliperidone palmitate) can cause side effects that range from mild to serious. More common side effects include injection site reactions. If side effects become difficult to tolerate ...

If approved, paliperidone palmitate 3-monthly injection will be the first once-every-three-months treatment for schizophrenia in the UK Janssen UK announced today that the Committee for Medicinal ...

The Food and Drug Administration has approved Invega Hafyera ™ (paliperidone palmitate), an every 6-month injection, for the treatment of schizophrenia in adults. Invega Hafyera is a long-acting ...

As with other drugs, Invega Sustenna (paliperidone palmitate) can cause side effects, such as excessive sleepiness and injection site reactions. If side effects of Invega Sustenna become difficult to ...

Invega may be prescribed as a long-term treatment. As with other drugs, Invega can cause side effects (also called adverse effects). Read on to learn about potential common, mild, and serious side ...

TITUSVILLE, N.J., May 24 /PRNewswire/ --New data on INVEGA® SUSTENNA® (paliperidone palmitate), a long-acting injectable medicine for schizophrenia, and new data on RISPERDAL® CONSTA® (risperidone ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. INVEGA SUSTENNA contains the active ingredient paliperidone palmitate.